Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on December 3, 2025. The report discloses a presentation made by the Company following its Annual Meeting of Stockholders on the same date. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Capital Market under the symbol GALT.
Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report serves solely to disclose the existence of a presentation transcript attached as an exhibit.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is limited to the disclosure of non-financial information regarding the Annual Meeting presentation.
Guidance, Outlook, and Risks
The filing references a transcript of the Annual Meeting presentation (Exhibit 99.1) which may contain management commentary or outlook, but the text of the 8-K itself does not summarize these details. The Company explicitly states that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the content of the Annual Meeting presentation by reviewing Exhibit 99.1 attached to this filing.
- Note that the information in this 8-K is furnished under Regulation FD and is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
- Confirm the Company's status as a Nevada corporation with a principal executive office in Norcross, GA.